Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | SMN1; SMN2 | Q16637 | 6/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 0.64 |
| ▸ | LMNA | P02545 | 4/20 | 0.61 |
| ▸ | HTT | P42858 | 3/20 | 0.61 |
| ▸ | CYP19A1 | P11511 | 5/20 | 0.59 |
| ▸ | MAPT | P10636 | 4/20 | 0.48 |
| ▸ | RAB9A | P51151 | 1/20 | 0.48 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.48 |
| ▸ | MEN1 | O00255 | 1/20 | 0.47 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.47 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.46 |
| ▸ | EYA2 | O00167 | 1/20 | 0.46 |
| ▸ | SLC22A12 | Q96S37 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6052442 | 0.84 | VCAM1 (0.53) | SMN1; SMN2ALDH1A1LMNAHTTCYP19A1 | |
| SCHEMBL11093863 | 0.82 | KDM4E (0.50) | SMN1; SMN2ALDH1A1LMNAHTTCYP19A1 | |
| SCHEMBL5570082 | 0.81 | MEN1 (0.48) | SMN1; SMN2ALDH1A1LMNAHTTCYP19A1 | |
| SCHEMBL2031800 | 0.81 | PPARG (0.52) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL30879375 | 0.81 | MEN1 (0.62) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL4033756 | 0.81 | MEN1 (0.62) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL2644891 | 0.81 | LMNA (0.62) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL29888811 | 0.81 | LMNA (0.62) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL1446664 | 0.81 | LMNA (0.62) | SMN1; SMN2ALDH1A1LMNAHTTMAPT | |
| SCHEMBL5565241 | 0.80 | HTT (0.60) | SMN1; SMN2ALDH1A1LMNAHTTMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | BRADBURY ROBERT H | 2007-10-04 | — | — | US | disclosed |
| EP-1756088-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | AstraZeneca AB (SE) | 2007-02-28 | — | — | EP | disclosed |
| WO-2005118572-A1 | QUINAZOLINE DERIVATIVES AS ERBB RECEPTOR TYROSINE KINASES | ASTRAZENECA AB (SE) | 2005-12-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070232607-A1 | Quinazoline Derivatives as Erbb Receptor Tyrosine kinases | ERBB2, ERBB3, ERBB4 | SMN1; SMN2 4594/4885ALDH1A1 3782/4885LMNA 3173/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.